Abstract
Hypomethylating Agent and Venetoclax Combination Therapy Yields Superior Outcomes When Compared to Hypomethylating Agent Monotherapy in Patients ≥70 Years with Acute Myeloid Leukemia
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have